KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease

Tissue Antigens

Volumn 78, Issue 2, 2011, Pages 129-138

  Karabon, L ^a   Jedynak, A ^a   Giebel, S ^b   Wolowiec, D ^c   Kielbinski, M ^c   Woszczyk, D ^d   Kapelko Slowik, K ^c   Kuliczkowski, K ^c   Frydecka, I ^a,c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d State Hospital   (Poland)

Author keywords

B cell chronic lymphocytic leukemia; Disease susceptibility; HLA ligand genes; KIR genes

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1;

ADULT; AGED; ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B CELL LEUKEMIA; CANCER SUSCEPTIBILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA ANTIGENS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIGANDS; MALE; MIDDLE AGED; PREVALENCE; RECEPTORS, KIR;

EID: 79959936624     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01721.x     Document Type: Article

References (43)

1. Goldin LR, Caporaso NE. Family studies in chronic lymphocytic leukaemia and other lymphoproliferative tumours. Br J Haematol 2007: 139: 774-9.
2. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003: 44: 383-9.
3. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004: 103: 4389-95.
4. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001: 250: 462-75.
5. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993: 14: 491-9.
6. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002: 100: 1935-47.
7. Chouaib S, Thiery J, Gati A et al. Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens 2002: 60: 273-81.
8. Burshtyn DN, Scharenberg AM, Wagtmann N et al. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 1996: 4: 77-85.
9. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998: 391: 703-07.
10. Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur J Immunol 2005: 35: 10-15.
11. Parham P. Immunogenetics of killer cell immunoglobulin-like receptors. Mol Immunol 2005: 42: 459-62.
12. Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008: 22: 249-57.
13. Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004: 18: 2002-07.
14. Zhang Y, Wang B, Ye S et al. Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: possible association with susceptibility to the disease. Leuk Res 2010: 34: 55-8.
15. Shahsavar F, Tajik N, Entezami KZ et al. KIR2DS3 is associated with protection against acute myeloid leukemia. Iran J Immunol 2010: 7: 8-17.
16. Middleton D, Diler AS, Meenagh A, Sleator C, Gourraud PA. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens 2009: 73: 553-60.
17. Giebel S, Nowak I, Wojnar J et al. Association of KIR2DS4 and its variant KIR1D with leukemia. Leukemia 2008: 22: 2129-30.
18. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008: 111: 5446-56.
19. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975: 46: 219-34.
20. Ploski R, Wozniak M, Pawlowski R et al. Homogeneity and distinctiveness of Polish paternal lineages revealed by Y chromosome microsatellite haplotype analysis. Hum Genet 2002: 110: 592-600.
21. Gomez-Lozano N, Vilches C. Genotyping of human killer-cell immunoglobulin-like receptor genes by polymerase chain reaction with sequence-specific primers: an update. Tissue Antigens 2002: 59: 184-93.
22. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002: 169: 5118-29.
23. Martin MP, Nelson G, Lee JH et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002: 169: 2818-22.
24. Vilches C, Castano J, Gomez-Lozano N, Estefania E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 2007: 70: 415-22.
25. Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol 2002: 168: 6208-14.
26. Yusa S, Catina TL, Campbell KS. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol 2002: 168: 5047-57.
27. Kikuchi-Maki A, Yusa S, Catina TL, Campbell KS. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol 2003: 171: 3415-25.
28. Verheyden S, Ferrone S, Mulder A et al. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells. Cancer Immunol Immunother 2009: 58: 855-65.
29. Alter G, Rihn S, Walter K et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009: 83: 6798-805.
30. Pende D, Marcenaro S, Falco M et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009: 113: 3119-29.
31. Martin MP, Gao X, Lee JH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002: 31: 429-34.
32. Stewart CA, Laugier-Anfossi F, Vely F et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 2005: 102: 13224-9.
33. Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 2007: 179: 5977-89.
34. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005: 5: 201-14.
35. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev 2006: 214: 186-201.
36. Passweg JR, Huard B, Tiercy JM, Roosnek E. HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends Immunol 2007: 28: 437-41.
37. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 2005: 54: 172-8.
38. Middleton D, Vilchez JR, Cabrera T et al. Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours. Tissue Antigens 2007: 69: 220-6.
39. Carrington M, Wang S, Martin MP et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 2005: 201: 1069-75.
40. Al OS, Middleton D, Marshall E et al. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 2010: 71: 976-81.
41. Du Z, Sharma SK, Spellman S, Reed EF, Rajalingam R. KIR2DL5 alleles mark certain combination of activating KIR genes. Genes Immun 2008: 9: 470-80.
42. Parham P. Influence of KIR diversity on human immunity. Adv Exp Med Biol 2005: 560: 47-50.
43. Giebel S, Locatelli F, Wojnar J et al. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol 2005: 131: 483-6.